New study checks if CMV drug reaches fetus in second trimester
NCT ID NCT04732260
First seen Sep 30, 2025 · Last updated Jun 16, 2026 · Updated 46 times
Summary
This study looked at how the drug letermovir passes from a pregnant woman to her fetus during the second trimester. Seven women who were already scheduled to end their pregnancy for other reasons took part. The goal was to measure drug levels in fetal blood and amniotic fluid to see if they are high enough to fight cytomegalovirus (CMV). This is a first step toward possibly using letermovir to treat CMV infection during pregnancy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANT WOMEN UNDERGOING TOP are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Necker - Enfants malades
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.